| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2009 | 1133 | 1.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2019 | 2544 | 0.980 |
Why?
|
| Lung Neoplasms | 28 | 2009 | 2365 | 0.880 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 344 | 0.590 |
Why?
|
| Paclitaxel | 14 | 2008 | 479 | 0.460 |
Why?
|
| Taxoids | 7 | 2010 | 126 | 0.370 |
Why?
|
| Sulfonamides | 2 | 2008 | 331 | 0.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2008 | 270 | 0.290 |
Why?
|
| Leukemia, Lymphoid | 11 | 1987 | 48 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 1077 | 0.270 |
Why?
|
| Antineoplastic Agents | 15 | 2008 | 2303 | 0.250 |
Why?
|
| Survival Rate | 12 | 2019 | 1948 | 0.250 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 308 | 0.240 |
Why?
|
| Combined Modality Therapy | 13 | 2010 | 1723 | 0.240 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 118 | 0.240 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 135 | 0.230 |
Why?
|
| Carboplatin | 8 | 2008 | 322 | 0.220 |
Why?
|
| Quinazolines | 4 | 2008 | 211 | 0.220 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1103 | 0.220 |
Why?
|
| Neoplasms | 9 | 2007 | 3169 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 244 | 0.200 |
Why?
|
| Aged | 33 | 2019 | 20430 | 0.200 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 1173 | 0.190 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 7061 | 0.180 |
Why?
|
| Neoplasm Staging | 11 | 2010 | 2017 | 0.180 |
Why?
|
| Bone Marrow | 8 | 1998 | 409 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2007 | 438 | 0.180 |
Why?
|
| Leukemia | 6 | 1982 | 301 | 0.180 |
Why?
|
| Adult | 35 | 2010 | 27918 | 0.170 |
Why?
|
| Drug Administration Schedule | 10 | 2009 | 829 | 0.170 |
Why?
|
| Fluorouracil | 4 | 2019 | 524 | 0.170 |
Why?
|
| Capecitabine | 2 | 2019 | 97 | 0.160 |
Why?
|
| Middle Aged | 33 | 2010 | 27569 | 0.160 |
Why?
|
| Organoplatinum Compounds | 4 | 2005 | 91 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2008 | 1914 | 0.160 |
Why?
|
| Camptothecin | 3 | 2008 | 196 | 0.160 |
Why?
|
| Male | 46 | 2016 | 44553 | 0.150 |
Why?
|
| Humans | 75 | 2019 | 93511 | 0.150 |
Why?
|
| Female | 47 | 2019 | 48698 | 0.150 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 1170 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 3 | 2002 | 115 | 0.140 |
Why?
|
| Etoposide | 3 | 2008 | 204 | 0.140 |
Why?
|
| Neutrophils | 3 | 2016 | 324 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 423 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 21 | 0.120 |
Why?
|
| Mast Cells | 1 | 2016 | 96 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 140 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 84 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2009 | 1524 | 0.110 |
Why?
|
| Methotrexate | 9 | 2019 | 225 | 0.110 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 278 | 0.110 |
Why?
|
| Leucovorin | 2 | 2005 | 200 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 3110 | 0.110 |
Why?
|
| Medical Oncology | 1 | 1998 | 404 | 0.110 |
Why?
|
| Doxorubicin | 7 | 2019 | 284 | 0.100 |
Why?
|
| Disease Progression | 6 | 2009 | 1531 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 259 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 603 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 477 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 9098 | 0.100 |
Why?
|
| Mitosis | 9 | 1978 | 150 | 0.090 |
Why?
|
| Agranulocytosis | 3 | 1984 | 16 | 0.090 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 401 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2009 | 208 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2008 | 231 | 0.080 |
Why?
|
| Brain Neoplasms | 4 | 2006 | 813 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 1073 | 0.080 |
Why?
|
| Neoplasm Metastasis | 6 | 2009 | 1061 | 0.080 |
Why?
|
| Child | 20 | 1998 | 7355 | 0.080 |
Why?
|
| Lymphoma | 3 | 1982 | 247 | 0.080 |
Why?
|
| Ifosfamide | 4 | 2003 | 37 | 0.080 |
Why?
|
| Prognosis | 11 | 2008 | 3910 | 0.070 |
Why?
|
| Cisplatin | 5 | 2010 | 568 | 0.070 |
Why?
|
| Cell Division | 4 | 1976 | 693 | 0.070 |
Why?
|
| Child, Preschool | 14 | 1998 | 3829 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2009 | 1448 | 0.070 |
Why?
|
| Eicosanoids | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 35 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 36 | 0.070 |
Why?
|
| Aging | 1 | 1993 | 727 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 99 | 0.070 |
Why?
|
| Vinblastine | 3 | 2002 | 85 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 80 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2008 | 150 | 0.060 |
Why?
|
| Infant | 13 | 1998 | 3220 | 0.060 |
Why?
|
| Bone Marrow Cells | 7 | 1976 | 264 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 84 | 0.060 |
Why?
|
| Cytarabine | 6 | 1982 | 216 | 0.060 |
Why?
|
| Guanine | 1 | 2007 | 194 | 0.060 |
Why?
|
| Asparaginase | 4 | 1982 | 35 | 0.060 |
Why?
|
| United States | 3 | 2008 | 7619 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 100 | 0.060 |
Why?
|
| Tegafur | 1 | 2005 | 17 | 0.060 |
Why?
|
| Drug Therapy, Combination | 8 | 1982 | 759 | 0.060 |
Why?
|
| Neuroblastoma | 3 | 1977 | 396 | 0.060 |
Why?
|
| Uracil | 1 | 2005 | 54 | 0.050 |
Why?
|
| Carbazoles | 1 | 2004 | 31 | 0.050 |
Why?
|
| Dipeptides | 1 | 2004 | 39 | 0.050 |
Why?
|
| Prodrugs | 1 | 2004 | 51 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 156 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 512 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 217 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1976 | 826 | 0.050 |
Why?
|
| Age Factors | 3 | 2019 | 1906 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1917 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 1660 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 65 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2002 | 54 | 0.050 |
Why?
|
| Anaphylaxis | 1 | 1982 | 30 | 0.040 |
Why?
|
| Insurance, Liability | 1 | 1981 | 9 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2001 | 472 | 0.040 |
Why?
|
| ErbB Receptors | 3 | 2009 | 506 | 0.040 |
Why?
|
| Bone Marrow Examination | 5 | 1987 | 40 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1981 | 57 | 0.040 |
Why?
|
| Research | 1 | 1981 | 251 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2802 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1982 | 515 | 0.040 |
Why?
|
| Tritium | 6 | 1982 | 116 | 0.040 |
Why?
|
| Thymidine | 6 | 1982 | 59 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1999 | 12 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 25 | 0.040 |
Why?
|
| Drug Combinations | 4 | 2005 | 200 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2001 | 657 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1993 | 210 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 17 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1999 | 28 | 0.040 |
Why?
|
| American Cancer Society | 1 | 1998 | 13 | 0.040 |
Why?
|
| Vincristine | 6 | 1982 | 99 | 0.040 |
Why?
|
| Karyotyping | 2 | 1993 | 222 | 0.040 |
Why?
|
| Kinetics | 5 | 1982 | 1492 | 0.030 |
Why?
|
| Esophagitis | 1 | 1998 | 40 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1999 | 220 | 0.030 |
Why?
|
| Blood Platelets | 2 | 2016 | 150 | 0.030 |
Why?
|
| Autoantibodies | 1 | 1999 | 277 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1977 | 32 | 0.030 |
Why?
|
| Adolescent | 11 | 1998 | 9606 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 361 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 7 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 14 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 30 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 255 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 49 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 80 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 1996 | 55 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 94 | 0.030 |
Why?
|
| Remission Induction | 2 | 2008 | 738 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1996 | 154 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 64 | 0.030 |
Why?
|
| Health Resources | 1 | 1996 | 80 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 248 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 192 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 171 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 444 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 215 | 0.030 |
Why?
|
| Aneuploidy | 2 | 2007 | 59 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 1987 | 313 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1275 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2001 | 158 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2007 | 335 | 0.030 |
Why?
|
| Time Factors | 5 | 2010 | 5410 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1243 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1996 | 298 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 502 | 0.030 |
Why?
|
| Premedication | 2 | 2003 | 57 | 0.020 |
Why?
|
| Leukopenia | 1 | 1993 | 64 | 0.020 |
Why?
|
| Autoradiography | 3 | 1982 | 53 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1993 | 224 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 1996 | 481 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 1338 | 0.020 |
Why?
|
| Acute Disease | 3 | 1982 | 841 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 576 | 0.020 |
Why?
|
| Blood Transfusion | 3 | 1984 | 175 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1971 | 266 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1741 | 0.020 |
Why?
|
| Risk | 3 | 1981 | 657 | 0.020 |
Why?
|
| Prednisone | 3 | 1982 | 242 | 0.020 |
Why?
|
| Chloramphenicol | 1 | 1969 | 13 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1970 | 183 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 32 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 1969 | 64 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2007 | 3054 | 0.020 |
Why?
|
| Cetuximab | 1 | 2009 | 118 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1987 | 125 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 86 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 140 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 33 | 0.020 |
Why?
|
| DNA | 4 | 1982 | 1265 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1987 | 439 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1985 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1967 | 6 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1967 | 2 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2010 | 326 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 2 | 1978 | 43 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 94 | 0.020 |
Why?
|
| Recurrence | 3 | 1999 | 1190 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 413 | 0.020 |
Why?
|
| Splenectomy | 2 | 1982 | 46 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 876 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 75 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 216 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 66 | 0.020 |
Why?
|
| Hydrocortisone | 3 | 1973 | 296 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1967 | 189 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 281 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 49 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 543 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 10 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 985 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 730 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 894 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 42 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 889 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 39 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 235 | 0.010 |
Why?
|
| Isoflurophate | 1 | 1964 | 3 | 0.010 |
Why?
|
| Phosphorus Isotopes | 1 | 1964 | 16 | 0.010 |
Why?
|
| Remission, Spontaneous | 3 | 1979 | 43 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 72 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 2 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 1984 | 8 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1984 | 18 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1984 | 14 | 0.010 |
Why?
|
| Granulocytes | 1 | 1984 | 35 | 0.010 |
Why?
|
| Quality of Life | 2 | 2005 | 1780 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1984 | 15 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 1964 | 51 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 398 | 0.010 |
Why?
|
| Probability | 2 | 1982 | 355 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1799 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1999 | 127 | 0.010 |
Why?
|
| Neutropenia | 1 | 1964 | 209 | 0.010 |
Why?
|
| Biopsy | 1 | 1987 | 1175 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 1001 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 27 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 30 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1395 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Erwinia | 1 | 1982 | 2 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 12269 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1984 | 179 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 2 | 1972 | 16 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2001 | 109 | 0.010 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1981 | 5 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 98 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 276 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1982 | 225 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 132 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 34 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 23 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 712 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 362 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1982 | 454 | 0.010 |
Why?
|
| Morals | 1 | 1981 | 102 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 293 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1982 | 664 | 0.010 |
Why?
|
| North America | 1 | 2000 | 195 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 688 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 756 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 373 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 62 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4560 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1982 | 563 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 88 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1999 | 5 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 6 | 0.010 |
Why?
|
| Europe | 1 | 2000 | 337 | 0.010 |
Why?
|
| Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1981 | 296 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1999 | 23 | 0.010 |
Why?
|
| Fingers | 1 | 1999 | 53 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 56 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 140 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 636 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1984 | 836 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 295 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 348 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1998 | 134 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1977 | 37 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 78 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1977 | 92 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 253 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 28155 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 229 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 158 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 988 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 309 | 0.010 |
Why?
|
| Phenotype | 1 | 1982 | 2544 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 457 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1977 | 293 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1998 | 2479 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1995 | 36 | 0.010 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 1974 | 2 | 0.010 |
Why?
|
| Phagocytosis | 2 | 1974 | 111 | 0.010 |
Why?
|
| Pediatrics | 1 | 1998 | 385 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 1973 | 9 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 990 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 617 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1973 | 145 | 0.010 |
Why?
|
| Bone Marrow Diseases | 2 | 1985 | 37 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1972 | 66 | 0.010 |
Why?
|
| Deoxyuridine | 1 | 1971 | 3 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 25 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1971 | 81 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3476 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1998 | 3828 | 0.010 |
Why?
|
| Injections, Spinal | 2 | 1982 | 48 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1971 | 260 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1970 | 285 | 0.000 |
Why?
|
| gamma-Globulins | 1 | 1967 | 15 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1967 | 15 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1967 | 44 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1972 | 2850 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1967 | 78 | 0.000 |
Why?
|
| Pedigree | 1 | 1967 | 961 | 0.000 |
Why?
|
| Pharmacogenetics | 1 | 1969 | 456 | 0.000 |
Why?
|
| Inflammation | 1 | 1970 | 1050 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1970 | 1621 | 0.000 |
Why?
|
| Mercaptopurine | 1 | 1982 | 53 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1979 | 69 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1978 | 13 | 0.000 |
Why?
|
| Orbital Neoplasms | 1 | 1978 | 16 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 141 | 0.000 |
Why?
|
| Facial Neoplasms | 1 | 1978 | 26 | 0.000 |
Why?
|
| Ear Neoplasms | 1 | 1978 | 14 | 0.000 |
Why?
|
| Ear, Middle | 1 | 1978 | 26 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1979 | 120 | 0.000 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1978 | 46 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1976 | 46 | 0.000 |
Why?
|
| Daunorubicin | 1 | 1976 | 77 | 0.000 |
Why?
|
| Sex Factors | 1 | 1979 | 1105 | 0.000 |
Why?
|
| Blood Bactericidal Activity | 1 | 1974 | 5 | 0.000 |
Why?
|
| Staphylococcus | 1 | 1974 | 24 | 0.000 |
Why?
|
| Candida albicans | 1 | 1974 | 32 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1974 | 128 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1974 | 94 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1974 | 74 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 158 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1974 | 278 | 0.000 |
Why?
|
| Lysosomes | 1 | 1974 | 123 | 0.000 |
Why?
|
| Leukocytes | 1 | 1974 | 210 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1974 | 948 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1974 | 603 | 0.000 |
Why?
|